Inactive Instrument

News Sunshine Heart Inc Nasdaq

Equities

US86782U1060

Summary

Unlock all the news on all businesses: Never miss an investment opportunity again!

Nuwellis Announces Launch of Ultrafiltration Therapy Using Aquadex Smartflow® System at Henry Ford Health	Apr. 09	AQ
Nuwellis, Inc. Announces Launch of Ultrafiltration Therapy Using Aquadex Smartflow® System at Henry Ford Health	Apr. 09	CI
Late-Breaking Data Highlighting Benefits of Ultrafiltration Therapy Using the Aquadex System for Heart Failure Patients was Presented at the Technology and Heart Failure Therapeutics Conference	Mar. 07	AQ
Nuwellis, Inc. Announces Results from Two New Clinical Data Analyses from the AVOID-HF Trial, Which Demonstrate the Benefits of its Aquadex System in Reducing Heart Failure Readmissions at 30 Days	Mar. 07	CI
Nuwellis, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023	Mar. 06	CI
Transcript : Nuwellis, Inc., Q4 2023 Earnings Call, Mar 05, 2024	Mar. 05
Earnings Flash (NUWE) NUWELLIS Reports Q4 Revenue $2.6M	Mar. 05	MT
Nuwellis, Inc. Announces Fourth Quarter and Full Year 2023 Financial Results	Mar. 05	AQ
Nuwellis, Inc. To Report Fourth Quarter and Full Year 2023 Financial Results on March 5, 2024	Feb. 27	AQ
Nuwellis’ Distribution Partner, SeaStar Medical, Receives FDA Humanitarian Device Exemption for Pediatric Selective Cytopheretic Device Quelimmune™	Feb. 22	AQ
Nuwellis, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	Feb. 20	AQ
Nuwellis to Announce Late-Breaking Clinical Data and Host Satellite Symposium at Technology and Heart Failure Therapeutics Conference	Feb. 20	AQ
New Case Series Demonstrates Potential of Aquadex Therapy for End-Stage Liver Disease Patients with Fluid Overload	Feb. 06	AQ
Certain Warrants of Nuwellis, Inc. are subject to a Lock-Up Agreement Ending on 16-JAN-2024.	Jan. 15	CI
Certain Stock Options of Nuwellis, Inc. are subject to a Lock-Up Agreement Ending on 16-JAN-2024.	Jan. 15	CI
Certain Common Stock of Nuwellis, Inc. are subject to a Lock-Up Agreement Ending on 16-JAN-2024.	Jan. 15	CI
Nuwellis Receives FDA Approval for Specialized Catheter	Jan. 04	MT
Nuwellis Receives FDA Clearance for an Additional Dual Lumen Extended Length Peripheral Catheter	Jan. 04	AQ
Nuwellis, Inc. Receives FDA Clearance for an Additional Dual Lumen Extended Length Peripheral Catheter	Jan. 04	CI
New Real-World Data Highlight the Clinical Benefits of Ultrafiltration Therapy with Hematocrit Monitoring for Pediatric Patients	Nov. 28	AQ

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

News Sunshine Heart Inc Nasdaq

Equities

US86782U1060

Summary

Filters